Isomorphic Labs raised $600 million in its first external funding round, led by Thrive Capital with participation from GV and ...

Isomorphic Labs, an Alphabet-backed AI biotech firm, raised $600M to boost its AI drug design engine, expand clinical ...

Isomorphic Labs, the AI drug-discovery platform that was spun out of Google's DeepMind in 2021, has raised external capital ...

AlphaFold 3, the improved version of the model used by Isomorphic Labs’ drug design engine, debuted last May. It can predict the shape of not only proteins but also DNA, RNA and other biological ...

In a major step toward more reliable AI-assisted molecular design, researchers from National Taiwan University have ...

The London-based business – which launched in 2021 – will use the funds to further its research, expand its team and continue on its mission to create new drugs and medicines using AI.

Isomorphic Labs says it is advancing drug design programs across multiple therapeutic areas and drug modalities. These include oncology and immunology, the primary focuses of the company's internal ...

Goldman Sachs estimates that AI drug discovery and breakthroughs like gene editing will add 0.5% to 2.5% to the U.S. gross ...

These new models mark OpenAI’s shift toward reasoning-based AI, but what does that mean? Simply put, unlike conventional ...